Timely diagnosis of mixed lineage leukemia (MLL) rearrangements in pediatric patients with B-cell precursor acute lymphoblastic leukemia (BP-ALL) is highly relevant in patient stratification. The presence of t(4;11)-MLL rearrangement is the most important criteria for high-risk stratification in protocols for childhood precursor BP-ALL. Current tests to identify t(4;11)-MLL involve karyotyping, fluorescence in situ hybridization and reverse transcription-PCR. The tests, however, are expensive both in terms of personnel and reagents. They do not provide a Results of mutational screening by sequence analyses revealing the K245E and the L284S mutations.
Letters to the Editor fast diagnosis and may fail due to technical reasons or high variability in the breakpoint that does not allow for standard reverse transcription-PCR detection. Therefore, a fast and reliable test that identifies MLL rearranged BP-ALL is highly welcome, particularly in low-income countries. Advances in identification of leukemia subtypes have been recently achieved using gene expression and flow cytometry (FC) techniques. These approaches were shown to be particularly relevant in the characterization of patients with MLL rearrangements, a recurrent disease that accounts for 5% of all leukemic subtypes and more than 50% in infants. Armstrong et al. 1 As NG2 antigen is negative in MLL(À) samples, a very low amount of positive blast cells for this marker is sufficient to suspect the presence of MLL rearrangements by qualitative FC. In this case, the quantified geometric mean for NG2 antigen could not be affected (producing a negative value for quantitative FC) because the sample shows only few positive events (case B).
The performance of the two FC methods has been calculated ( Table 2) . Twenty-seven (90.0%) and 26 (86.7%) out of thirty cases were correctly diagnosed as true positive according to GS MLL identification using qualitative and quantitative FC, respectively (true positive (TP)). MESF analysis correctly Table 2) .
MLL aberrations have been proved to share common features in different hematological diseases identifying NG2 antigen as an accurate marker for the presence of MLL rearrangements. 2, [5] [6] [7] Attarbaschi et al. 8 recently published a study, on behalf of the BFM cooperative study group, in which they report absolute sensitivity and 0.78 specificity for absence of CD10 expression (CD10À) in pro-B and pre-B ALL as phenotypic marker for predicting MLL rearrangements. Our results show that the absence of CD10 in BP-ALL patients with MLL rearrangements has very low specificity (28/86, 32.56%), while the presence of NG2 accounts for high sensitivity (87-90%) and specificity (99-100%). Furthermore, in 2 out of 30 MLL-positive cases analyzed by GS methods, the rearrangement was found in CD10( þ ) samples: one in a patient with CALL and one in a patient with pre-B ALL. While Attarbaschi et al. 8 question the use of NG2 as a marker for MLL rearranged BPC-ALL, we point out that NG2 expression, evaluated by a combination of 
